The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
Genitourinary
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
Published in The New England Journal of Medicine (1) results of the phase 3 COSMIC-313 trial show that the addition…
A study in which the VHIO has participated would seem to show that the combination of durvalumab, an anti-PD-L1 monoclonal…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
